Clinical trials: Disorder, Mood
Major Depressive Disorder
A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder
This is a study with an Open-Label (OL) phase followed by a randomized, Double-Blind (DB), placebo-controlled phase to assess efficacy and safety of SAGE-217 on relapse prevention in adults with major depressive disorder (MDD).
- Trial name
- NCT04007367
- Testing
- SAGE-217
- Where
- 46 sites in United States
- Volunteers
- 53 people
- Sponsor
- Biogen
Generalized Anxiety Disorder
An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in treating Generalized Anxiety Disorder.
- Trial name
- NCT00734071
- Testing
- Vortioxetine
- Where
- 33 sites in United States
- Volunteers
- 304 people
- Sponsor
- Takeda
Major Depressive Disorder
A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy in patients with major depressive disorder.
- Trial name
- NCT02395978
- Testing
- PDC-1421 Capsule
- Where
- 5 sites in United States, Taiwan
- Volunteers
- 72 people
- Sponsor
- BioLite, Inc.
Major Depressive Disorder
Post Marketing Study for the Evaluation of Predictix Antidepressant Clinician Software Support Tool in Prescribing Antidepressant Medication/s for the Treatment of Patients Suffering From Major Depressive Disorder
The study is designed as an open label, one arm study. Up to 30 eligible patients will be enrolled, for whom the Predictix Antidepressant Software tool will be used when prescribed with a medication for their Major Depressive…
- Trial name
- NCT04138290
- Testing
- Predictix Antidepressant Software tool
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Taliaz Ltd.
Major Depressive Disorder
Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers
To evaluate the safety, tolerability, pharmacokinetics and EEG pharmacodynamics of single and multiple ascending doses of apimostinel in normal human volunteers
- Trial name
- NCT05597241
- Testing
- apimostinel
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Syndeio Biosciences, Inc
Major Depressive Disorder
Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders
The purpose of this study is to evaluate the efficacy of quetiapine SR in combination with an antidepressant versus an antidepressant alone in patients with MDD with inadequate response to an antidepressant treatment.
- Trial name
- PEARL (NCT00326105)
- Testing
- Quetiapine fumarate
- Where
- 56 sites in United States
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Depressive Disorder, Major
A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Extended-release Bupropion Hydrochloride Tablets in Chinese Healthy Volunteers
Bupropion is used in psychological disorder mainly in major depressive disorder (MDD). In China, buproprion Immediate Release (IR) and Sustained Release (SR) tablet have been in market for the treatment of MDD.
- Trial name
- NCT02698553
- Testing
- Bupropion HCl XL tablet 150mg, Bupropion HCl XL tablet 300mg
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Depression, Bipolar Disorder
Quantified Mobile Sensing for Improving Diagnosis and Measuring Disease Progression
The purpose of this study is to determine if a mobile sensing platform can passively and objectively detect the presence of clinically significant mood disorder symptomatology and symptom progression over time.
- Trial name
- NCT02742064
- Testing
- Cogito Companion Mobile Phone Application
- Where
- United States
- Volunteers
- 899 people
- Sponsor
- Cogito Health Inc
Depressive Disorder
Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions
The objective of this study is to evaluate the comparative bioavailability between bupropion hydrochloride 300 mg extended release tablets (Teva Pharmaceuticals USA) and Wellbutrin XL® 300 mg extended release tablets (Biovail…
- Trial name
- NCT01046214
- Testing
- Bupropion HCl
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Teva Pharmaceuticals USA
Schizophrenia, Schizoaffective Disorder
A Study of QT and QTc Intervals in Patients Administered Immediate Release Paliperidone
The purpose of this study is to assess the cardiovascular safety of paliperidone in patients with schizophrenia or schizoaffective disorder, with particular attention to the length of the QT/QTc interval, to measure and review…
- Trial name
- NCT00791349
- Testing
- Immediate release (IR) Paliperidone
- Volunteers
- 141 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Major Depressive Disorder
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major…
- Trial name
- X-NOVA3 (NCT07076407)
- Testing
- Azetukalner
- Where
- 50 sites in United States, Finland and 5 more
- Volunteers
- 450 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Major Depressive Disorder, Bi-Polar Disorder
DELPhI Evaluation of Psychiatric Conditions
DELPhI acquisition and analysis software, a QuantalX Neuroscience development, which is designed to measure, analyze, and display brain electrical activity of human electroencephalogram (EEG), to transcranial magnetic stimulation…
- Conditions
- Major Depressive Disorder, Bi-Polar Disorder, ADHD, Schizophrenia
- Trial name
- NCT03842345
- Sponsor
- QuantalX Neuroscience
Bipolar Disorder
A Study of the Relationship of Psychosocial Function With Mood Symptoms in Offspring of Parents With Bipolar Disorder
The primary purpose of this study is to compare, over 24 months, the time spent with clinically significant mood symptoms (ie, mania, depression), as measured by the Longitudinal Interval Follow-Up Evaluation (LIFE) and the…
- Trial name
- NCT03017781
- Where
- 20 sites in United States
- Volunteers
- 224 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression
The purpose of this study is to compare the efficacy of vortioxetine versus desvenlafaxine after 8 weeks of treatment in patients that have tried one available treatment without getting the full benefit
- Trial name
- VIVRE (NCT04448431)
- Testing
- Vortioxetine, Desvenlafaxine
- Where
- 80 sites in Argentina, Belgium and 10 more
- Volunteers
- 605 people
- Sponsor
- H. Lundbeck A/S
Bipolar Disorder
Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)
The purpose of this study is to determine if flexibly-dosed ziprasidone is safe and effective for the treatment of children and adolescents (ages 10-17) with bipolar I disorder (manic or mixed).
- Trial name
- NCT00257166
- Testing
- Ziprasidone oral capsules
- Where
- 50 sites in United States
- Volunteers
- 238 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Depressive Disorder
Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients
This is an open label, randomized, add-on, 8 weeks multicentre study to evaluate the efficacy and safety of paroxetine Controlled Release (CR) in patients with Major Depressive Disorder (MDD) comorbid Irritable Bowel Syndrome…
- Trial name
- NCT01916200
- Testing
- Paroxetine CR
- Sponsor
- GlaxoSmithKline
Bipolar Disorder
Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder
The purpose of this study is to learn if aripiprazole is effective for the treatment of patients with acute symptoms of Bipolar disorder.
- Trial name
- NCT00036101
- Testing
- aripiprazole
- Where
- 27 sites in United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Depression, Suicidal Ideation and Behavior
NRX-101 for Bipolar Depression With Subacute Suicidal Ideation
NMDA antagonist drugs have shown to reduce symptoms of depression and suicidal ideation. NeuroRx has developed NRX-101 (fixed dose combination of D-cycloserine and lurasidone) for oral use in the treatment of bipolar depression…
- Trial name
- NCT03395392
- Testing
- NRX-101, Lurasidone HCl
- Where
- 14 sites in United States
- Volunteers
- 74 people
- Sponsor
- NeuroRx, Inc.
Major Depressive Disorder
ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment
This multi-center, randomized, double-blind, placebo-controlled, parallel-group study will investigate the efficacy and safety of RO4995819 as adjunctive therapy in patients with major depressive disorder having inadequate…
- Trial name
- NCT01457677
- Testing
- RO4995819
- Where
- 92 sites in United States, Austria and 6 more
- Volunteers
- 357 people
- Sponsor
- Hoffmann-La Roche
Bipolar Disorder
Study to Assess the Effect of Food on the Concentration of GW273225 in the Body of Healthy Male and Female Volunteers
The rationale of this study is to assess whether or not food affects the absorption of GW273225 into the blood of healthy male and female volunteers in order to evaluate whether or not this drug should be given at a certain time…
- Trial name
- NCT00501865
- Testing
- GW273225
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.